Subd. 14.

Wholesale drug distributor prescription drug substantial public interest
reporting.

(a) Beginning January 1, 2024, a wholesale drug distributor must submit to the
commissioner the information described in paragraph (b) for any prescription drug included
in a notification to report issued to the wholesale drug distributor by the department under
subdivision 10.

(b) For each of the drugs described in paragraph (a), the wholesale drug distributor shall
submit to the commissioner no later than 60 days after the date of the notification to report,
in the form and manner prescribed by the commissioner, the following information, if
applicable:

(1) a description of the drug with the following listed separately:

(i) the national drug code;

(ii) the product name;

(iii) the dosage form;

(iv) the strength; and

(v) the package size;

(2) the number of units of the drug product acquired new text begin each month new text end by the wholesale drug
distributor during the 12-month period prior to the date of the notification to report;

(3) the total spent before rebates new text begin each month new text end by the wholesale drug distributor to acquire
the drug product during the 12-month period prior to the date of the notification to report;

(4) the total rebate receivable amount accrued new text begin each month new text end by the wholesale drug
distributor for the drug product during the 12-month period prior to the date of the notification
to report;

(5) the number of units of the drug product sold new text begin each month new text end by the wholesale drug
distributor during the 12-month period prior to the date of the notification to report;

(6) gross revenue from sales in the United States generated new text begin each month new text end by the wholesale
drug distributor for this drug product during the 12-month period prior to the date of the
notification to report; and

(7) total rebate payable amount accrued new text begin each month new text end by the wholesale drug distributor
for the drug product during the 12-month period prior to the date of the notification to report.

(c) The wholesale drug distributor may submit any documentation necessary to support
the information reported under this subdivision.